NASDAQ: CUPRCuprina Holdings Ltd Stock
$0.59+0.09 (+18%)
Updated Dec 12, 2025
CUPR Price
$0.59
Fair Value Price
-$0.11
Market Cap
$12.70M
52 Week Low
$0.48
52 Week High
$9.50
P/E
-5.15x
P/B
2.15x
P/S
4,803.28x
PEG
N/A
Dividend Yield
N/A
Revenue
$23.33k
Earnings
-$2.21M
Gross Margin
-69.2%
Operating Margin
-9,305.22%
Profit Margin
-9,335.7%
Debt to Equity
0.41
Operating Cash Flow
-$7M
Beta
0.61
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CUPR Overview
Cuprina Holdings (Cayman) Limited is a Singapore-based biomedical and biotechnology company dedicated to developing and commercializing innovative products for managing chronic wounds. The company manufactures and distributes medical-grade sterile blowfly larvae bio-dressing products under the MEDIFLY brand, used as a biological debridement tool for chronic wounds. Additionally, Cuprina operates in the health and beauty sectors, offering cosmeceutical products.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CUPR's potential to beat the market
- CUPR doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
CUPR
RankedUnranked of 45
RankedUnranked of 45
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $5.02 | A | |
| $9.24 | A | |
| $21.97 | A |
Be the first to know about important CUPR news, forecast changes, insider trades & much more!
CUPR News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CUPR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CUPR ($0.59) is overvalued by 625.66% relative to our estimate of its Fair Value price of -$0.11 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CUPR ($0.59) is not significantly undervalued (625.66%) relative to our estimate of its Fair Value price of -$0.11 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CUPR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CUPR due diligence checks available for Premium users.
Valuation
CUPR fair value
Fair Value of CUPR stock based on Discounted Cash Flow (DCF)
Price
$0.59
Fair Value
-$0.11
Undervalued by
623.89%
CUPR ($0.59) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CUPR ($0.59) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CUPR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CUPR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.15x
Industry
216.44x
Market
45x
CUPR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.15x
Industry
3.7x
CUPR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CUPR's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
CUPR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CUPR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$8.5M
Liabilities
$2.5M
Debt to equity
0.41
CUPR's short-term assets ($8.28M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CUPR's short-term assets ($8.28M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CUPR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
CUPR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CUPR vs Medical Stocks
Cuprina Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.